![(1-(2'-(1-Nitroso-1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)-2-oxohexyl)-L-valine](https://veeprho.com/wp-content/uploads/2022/07/1-2-1-Nitroso-1H-tetrazol-5-yl-11-biphenyl-4-yl-2-oxohexyl-L-valine-1.png)
(1-(2′-(1-Nitroso-1H-tetrazol-5-yl)-[1,1′-biphenyl]-4-yl)-2-oxohexyl)-L-valine
(1-(2′-(1-Nitroso-1H-tetrazol-5-yl)-[1,1′-biphenyl]-4-yl)-2-oxohexyl)-L-valine is an impurity present in Valsartan, Valsartan belongs to the angiotensin II receptor blocker, ARBs selectively bind to angiotensin receptor 1 (AT1) and prevent the protein angiotensin II from binding and exerting its hypertensive effect, or in combination with other antihypertensive agents and to manage heart failure in patients who are intolerant to ACE inhibitors.
Additional information on (1-(2'-(1-Nitroso-1H-tetrazol-5-yl)-[1 | 1'-biphenyl]-4-yl)-2-oxohexyl)-L-valine
VE009745
N/A
C24H28N6O4
464.5 g/mol
Valsartan
(1-(2'-(1-Nitroso-1H-tetrazol-5-yl)-[1, 1'-biphenyl]-4-yl)-2-oxohexyl)-L-valine
N/A
"Abraham, I. (2011). Real-world effectiveness of valsartan on hypertension and total cardiovascular risk: review and implications of a translational research program. Vascular Health and Risk Management, 209. https://doi.org/10.2147/vhrm.s9434 "
Under Development
